SERA seraprognostics.com: Business Value to Revenue

Sera Prognostics (SERA) - corporate logo

Sera Prognostics (SERA) is recognized by gynecologists for its innovative tests identifying risks of preterm birth. Support from leading US insurers ensures a stable capital inflow and high profitability. The company's price-to-sales ratio confirms the valuation trend, where the 351400.00 mark reflects the current state. However, challenges in integrating diagnostics into clinical practice and marketing expenses are hindering the path to profitability.

SERA Sera Prognostics Inc. Company Value to Revenue (11/23/2025 - 11/19/2026)

SERA (Sera Prognostics): analytical breakdowns and indicator data

- price and consensus price forecast:
- company stock capitalization data:
Initial company analysis:SERA, Sera Prognostics
Brand item of Sera Prognostics Inc.

The EV/Sales ratio determines the value of a business, including net debt, relative to sales volume. This metric allows for an assessment of the market premium paid per unit of revenue regardless of financial leverage. By analyzing the historical EV/Sales trend, an investor can identify asset overheating amid tight monetary policy. The indicator's dynamics reflect market expectations for business scaling. For Sera Prognostics (SERA), this correlates with the adoption rate of the PreTRM test into government protocols and the expansion of insurance coverage.